You are here

Survey: Gastroenterologists Applaud Cell Adhesion Molecule Inhibitor Vedolizumab (Entyvio)

Treatment offers different mechanism of action

Decision Resources Group, a health care research firm located in Burlington, Mass., has found that at 1 month post-launch, most surveyed gastroenterologists were aware of and familiar with vedolizumab (Entyvio, Takeda) as a new therapy for the treatment of moderate-to-severe ulcerative colitis (UC) and/or Crohn’s disease (CD).

According to surveyed gastroenterologists, the most commonly cited advantage of vedolizumab compared with other currently available biologic treatments was its different mechanism of action. At 1 month post-launch, less than 20% of surveyed gastroenterologists reported prescribing vedolizumab to their UC and/or CD patients.

Less than half of surveyed gastroenterologists were satisfied with the currently available products for moderate-to-severe UC and/or CD, and most agreed that there is a need for alternative therapies.

Although the risk of progressive multifocal leukoencephalopathy associated with vedolizumab was a concern for most surveyed gastroenterologists, most of the respondents anticipated prescribing the agent to their patients with UC and/or CD within 1 year.

According to surveyed gastroenterologists, tumor necrosis factor (TNF)-refractory patients with UC and/or CD are the ideal candidates for treatment with vedolizumab. Infliximab (Remicade, Janssen Biotech) and adalimumab (Humira, AbbVie) are likely to remain the first-line biologic agents for patients with moderate-to-severe UC and/or CD.

“High opportunity exists for emerging therapies in the inflammatory bowel disease market,” said analyst Adi Reske, PhD. “Improved efficacy in the acute and maintenance setting, long-term safety, and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD.”

Source: BioTrends Research Group; September 29, 2014.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Attacks Cancerous Cells, Leaves Healthy Tissues Alone